Pharmacyclics, Janssen win early Imbruvica label expansion in CLL

Pharmacyclics and Janssen Biotech won full US FDA approval and an expanded the label for their drug Imbruvica (ibrutinib) in the treatment of chronic lymphocytic leukemia (CLL) just five months after getting accelerated approval for the Bruton's tyrosine kinase (BTK) inhibitor for previously treated CLL patients.